TY - JOUR
T1 - Report from the CVOT Summit 2021
T2 - new cardiovascular, renal, and glycemic outcomes
AU - Schnell, Oliver
AU - Battelino, Tadej
AU - Bergenstal, Richard
AU - Blüher, Matthias
AU - Böhm, Michael
AU - Brosius, Frank
AU - Carr, Richard D.
AU - Ceriello, Antonio
AU - Forst, Thomas
AU - Giorgino, Francesco
AU - Guerci, Bruno
AU - Heerspink, Hiddo J.L.
AU - Itzhak, Baruch
AU - Ji, Linong
AU - Kosiborod, Mikhail
AU - Lalić, Nebojša
AU - Lehrke, Michael
AU - Marx, Nikolaus
AU - Nauck, Michael
AU - Rodbard, Helena W.
AU - Rosano, Giuseppe M.C.
AU - Rossing, Peter
AU - Rydén, Lars
AU - Santilli, Francesca
AU - Schumm-Draeger, Petra Maria
AU - Vandvik, Per Olav
AU - Vilsbøll, Tina
AU - Wanner, Christoph
AU - Wysham, Carol
AU - Standl, Eberhard
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18–19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed CVOTs. This year’s focus was placed on the outcomes of EMPEROR-Preserved, FIGARO-DKD, AMPLITUDE-O, SURPASS 1–5, and STEP 1–5. Trial implications for diabetes and obesity management and the impact on new treatment algorithms were highlighted for endocrinologists, diabetologists, cardiologists, nephrologists, and general practitioners. Discussions evolved from outcome trials using SGLT2 inhibitors as therapy for heart failure, to CVOTs with nonsteroidal mineralocorticoid receptor antagonists and GLP-1 receptor agonists. Furthermore, trials for glycemic and overweight/obesity management, challenges in diabetes management in COVID-19, and novel guidelines and treatment strategies were discussed. Trial registration The 8th Cardiovascular Outcome Trial Summit will be held virtually on November 10–11, 2022 (http://www.cvot.org).
AB - The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18–19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed CVOTs. This year’s focus was placed on the outcomes of EMPEROR-Preserved, FIGARO-DKD, AMPLITUDE-O, SURPASS 1–5, and STEP 1–5. Trial implications for diabetes and obesity management and the impact on new treatment algorithms were highlighted for endocrinologists, diabetologists, cardiologists, nephrologists, and general practitioners. Discussions evolved from outcome trials using SGLT2 inhibitors as therapy for heart failure, to CVOTs with nonsteroidal mineralocorticoid receptor antagonists and GLP-1 receptor agonists. Furthermore, trials for glycemic and overweight/obesity management, challenges in diabetes management in COVID-19, and novel guidelines and treatment strategies were discussed. Trial registration The 8th Cardiovascular Outcome Trial Summit will be held virtually on November 10–11, 2022 (http://www.cvot.org).
KW - Blood Glucose
KW - COVID-19
KW - Cardiovascular Diseases/drug therapy
KW - Clinical Trials as Topic
KW - Diabetes Mellitus/drug therapy
KW - Humans
KW - Hypoglycemic Agents/therapeutic use
KW - Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
KW - Treatment Outcome
UR - https://www.scopus.com/pages/publications/85127836619
U2 - 10.1186/s12933-022-01481-0
DO - 10.1186/s12933-022-01481-0
M3 - Comment/debate
C2 - 35395808
AN - SCOPUS:85127836619
SN - 1475-2840
VL - 21
SP - 50
JO - Cardiovascular Diabetology
JF - Cardiovascular Diabetology
IS - 1
M1 - 50
ER -